Pancreatic triglyceride lipase mediates lipotoxic systemic inflammation

Visceral adipose tissue plays a critical role in numerous diseases. Although imaging studies often show adipose involvement in abdominal diseases, their outcomes may vary from being a mild self-limited illness to one with systemic inflammation and organ failure. We therefore compared the pattern of visceral adipose injury during acute pancreatitis and acute diverticulitis to determine its role in organ failure. Acute pancreatitis-associated adipose tissue had ongoing lipolysis in the absence of adipocyte triglyceride lipase (ATGL). Pancreatic lipase injected into mouse visceral adipose tissue hydrolyzed adipose triglyceride and generated excess nonesterified fatty acids (NEFAs), which caused organ failure in the absence of acute pancreatitis. Pancreatic triglyceride lipase (PNLIP) increased in adipose tissue during pancreatitis and entered adipocytes by multiple mechanisms, hydrolyzing adipose triglyceride and generating excess NEFAs. During pancreatitis, obese PNLIP-knockout mice, unlike obese adipocyte-specific ATGL knockouts, had lower visceral adipose tissue lipolysis, milder inflammation, less severe organ failure, and improved survival. PNLIP-knockout mice, unlike ATGL knockouts, were protected from adipocyte-induced pancreatic acinar injury without affecting NEFA signaling or acute pancreatitis induction. Therefore, during pancreatitis, unlike diverticulitis, PNLIP leaking into visceral adipose tissue can cause excessive visceral adipose tissue lipolysis independently of adipocyte-autonomous ATGL, and thereby worsen organ failure

Synthesis and characterization of aluminum doped zinc oxide nanostructures via hydrothermal route

Stable crystalline aluminum doped zinc oxide (AZO) nanopowders were synthesized using hydrothermal treatment processing. Three different aluminum precursors have been used. The Al-precursors were found to affect the morphology of the obtained nanopowders. AZO nanoparticles based on zinc acetate and aluminum nitrate have been prepared with different Al/Zn molar ratios. XRD investigations revealed that all the obtained powders have single phase zincite structure with purity of about 99%. The effect of aluminum doping ratio in AZO nanoparticles (based on Al-nitrate precursor) on structure, phase composition, and particle size has been investigated. The incorporation of Al in ZnO was confirmed by UV-Vis spectroscopy revealing a blue shift due to Burstein-Moss effect

General Relativistic Mean Field Theory for Rotating Nuclei

We formulate a general relativistic mean field theory for rotating nuclei starting from the special relativistic $\sigma - \omega$ model Lagrangian. The tetrad formalism is adopted to generalize the model to the accelerated frame.Comment: 13 pages, REVTeX, no figures, submitted to Phys. Rev. Lett., the word `curved' is replaced by `non-inertial' or `accelerated' in several places to clarify the physical situation interested, some references are added, more detail discussions are given with omitting some redundant sentence

Production of bacteriocin-like inhibitory substances (BLIS) by Bifidobacterium lactis using whey as a substrate

The objective of this work was to evaluate the production of bacteriocin-like inhibitory substances (BLIS) by Bifidobacterium animalis subsp. lactis in whey supplemented with yeast extract, inulin, Tween 80 or L-cysteine. Cell growth, acidification, glucose and lactose consumption as well as BLIS production were measured during fermentations carried out in shake flasks. The best additive for both cell growth and BLIS production was shown to be yeast extract, which gave the highest concentrations of biomass (9.9 log CFU/mL) and BLIS (800 AU/mL). In a bench-scale fermenter, B. lactis growth and BLIS production were between 6 and 25 % higher than in flasks depending on the conditions assayed

Persistence and Adherence to Cardiovascular Medicines in Australia

BACKGROUND: The burden of cardiovascular disease is increasing, with many people treated for multiple cardiovascular conditions. We examined persistence and adherence to medicines for cardiovascular disease treatment or prevention in Australia. METHODS AND RESULTS: Using national dispensing claims for a 10% random sample of people, we identified adults (≥18 years) initiating antihypertensives, statins, oral anticoagulants, or antiplatelets in 2018. We measured persistence to therapy using a 60-day permissible gap, and adherence using the proportion of days covered up to 3 years from initiation, and from first to last dispensing. We reported outcomes by age, sex, and cardiovascular multimedicine use. We identified 83 687 people initiating antihypertensives (n=37 941), statins (n=34 582), oral anticoagulants (n=15 435), or antiplatelets (n=7726). Around one-fifth of people discontinued therapy within 90 days, with 50% discontinuing within the first year. Although many people achieved high adherence (proportion of days covered ≥80%) within the first year, these rates were higher when measured from first to last dispensing (40.5% and 53.2% for statins; 55.6% and 80.5% for antiplatelets, respectively). Persistence was low at 3 years (17.5% antiplatelets to 37.3% anticoagulants). Persistence and adherence increased with age, with minor differences by sex. Over one-third of people had cardiovascular multimedicine use (reaching 92% among antiplatelet users): they had higher persistence and adherence than people using medicines from only 1 cardiovascular group. CONCLUSIONS: Persistence to cardiovascular medicines decreases substantially following initiation, but adherence remains high while people are using therapy. Cardiovascular multimedicine use is common, and people using multiple cardiovascular medicines have higher rates of persistence and adherence